These antigens are generally categorized into two types: TAAs, which are normally found in the body but are overexpressed in cancer cells; and tumor neoantigens, which are the result of genetic mutations exclusive to tumor cells and are detected by antigen-specific T cell receptors (TCRs) in conjunction with major histocompatibility complex (MHC) molecules. This evidence concerns the gene HLA-C and neoplasm.